APODRUG Novel fusion protein for clinical management of diabetes mellitus associated with fatty liver disease

  • Edition: 2016
  • Research center: Centro para la Investigación Médica Aplicada
  • Scientific Area: Pharmacology
  • Business area: Therapeutic
  • Status: In development
  • Contact: pberraondol@unav.es

Long-lasting insulins are insulin formulations used in the treatment of diabetes to control fasting glucose. Chronic insulin resistance is aggravated by its lipogenic activity that generates hepatic steatosis and weight gain, thereby worsening insulin resistance. The proposed fusion protein is designed to avoid liver lipid accumulation.

Goals

  • The program aims to develop a novel fusion protein for the treatment of diabetic patients with an associated fatty liver disease.

See project infographic:

Infographic

Problem to Solve

Diabetes mellitus is a serious disease characterized by the lack of control of the amount of sugar in the blood. This condition is often associated with other metabolic diseases such as fatty liver disease. However, current treatments for diabetes are only focused on the glucose control and may be detrimental for the liver disease. The prevalence of diabetic patients with an associated fatty liver disease is estimated to be of 13% in Spain, in people over 18-years-old, and 40% in patients over 75 years of age.

Innovation

At CIMA (Center for Applied Medical Research, University of Navarra), we have designed a fusion protein aimed at improving both the control of glucose and at ameliorating the liver disease.

Level of Innovation

Long-lasting insulins are insulin formulations used in the treatment of diabetes to control fasting glucose. Chronic insulin resistance is aggravated by its lipogenic activity that generates hepatic steatosis and weight gain, thereby worsening insulin resistance. The proposed fusion protein is designed to avoid liver lipid accumulation. This new drug may have a strong impact in the society since the incidence of diabetes associated with fatty liver disease is growing rapidly and can be considered a pandemic. The new drug will contribute to improving the management of the people suffering from metabolic syndrome.

Team

Pharm.D., Coordinator. Researcher

Pedro Berraondo

CIMA - Centro de Investigación Médica Aplicada. Universidad de Navarra

MD, Endocrinology consultant

Dr. Javier Escalada

UNAV - Universidad de Navarra

PhD, Director of small molecules platform

Dr. Julen Oyarzabal.

CIMA - Centro de Investigación Médica Aplicada. Universidad de Navarra

Partners

Obra Social
Caixa Capital Risc